Accueil › Leucémie lymphocytaire chronique › Massachusetts › Boston
Essais cliniques pour Leucémie lymphocytaire chronique à Boston, MA
31 études pour Leucémie lymphocytaire chronique recherchent des participants dans et autour de Boston (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Recrutement en coursPhase 3
- Dana-Farber Cancer Institute, Boston
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Recrutement en coursPhase 3
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Recrutement en coursPhase 3
- Beth Israel Deaconess Medical Center (Bidmc), Boston
- Dana Farber Cancer Institute, Boston
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Recrutement en coursPhase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Recrutement en coursPhase 3
- Dana Farber Cancer Institute, Boston
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Recrutement en coursPhase 1/2
- Dana Farber Cancer Institute, Boston
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recrutement en coursPhase 3
- Dana Farber Cancer Institute, Boston
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Recrutement en coursPhase 2
- Dana-Farber Cancer Institute, Boston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Recrutement en coursPhase 1/2
- Research Site, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Recrutement en coursPhase 1
- Tufts Medical Center, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Recrutement en coursPhase 1/2
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Recrutement en coursPhase 4
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Recrutement en coursPhase 2
- Massachusetts General Hospital, Boston
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Recrutement en coursPhase 2
- Research Site, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Recrutement en coursPhase 1Volontaires sains bienvenus
- Brigham and Women's Hospital, Boston
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recrutement en coursPhase 2
- Boston Medical Center, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Recrutement en coursÉtude observationnelle
- Dana-Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Recrutement en coursPhase 1
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Recrutement en coursÉtude observationnelle
- Dana-Farber Cancer Institute, Boston
Understanding Chronic Lymphocytic Leukemia
Recrutement en coursÉtude observationnelle
- Dana Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Recrutement en coursPhase 2Volontaires sains bienvenus
- DFCI/BWH Brigham and Women's Hospital, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Recrutement en coursPhase 4
- Dana-Farber Cancer Institute, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Recrutement en coursPhase 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Recrutement en coursPhase 1
- Beth Israel Deaconess Medical Center, Boston
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Recrutement en coursPhase 1/2
- Dana-Farber Cancer Institute, Boston
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Recrutement en coursPhase 2
- Dana-Farber Cancer Institute /ID# 230061, Boston
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Recrutement en coursPhase 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Recrutement en coursPhase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
Recrutement en coursPhase 1/2
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Recrutement en coursPhase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Recrutement en coursPhase 1
- Dana-Farber Cancer Institute, Boston
Essais pour Leucémie lymphocytaire chronique dans d'autres villes
- Columbus, OH28 études
- Durham, NC27 études
- Washington, DC22 études
- Seattle, WA20 études
- Rochester, MN19 études
- New York City, NY18 études
- Houston, TX17 études
- Baldwin Park, CA16 études
- Milwaukee, WI15 études
- Cincinnati, OH14 études
- Chicago, IL14 études
- Nashville, TN13 études
Autres études à Boston
- Cancer du sein111 études
- Cancer du poumon non à petites cellules90 études
- Cancer (tous types)86 études
- Cancer colorectal63 études
- Cancer métastatique63 études
- Cancer du poumon62 études
- Cancer de l'ovaire61 études
- Cancer de la prostate59 études
- Dépression52 études
- Cancer de l'endomètre50 études
- Insuffisance cardiaque44 études
- Leucémie aiguë myéloïde44 études
Source : ClinicalTrials.gov, données récupérées le 5 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.